Stonebridge Capital Advisors’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-32
| Closed | -$3.26K | – | 625 |
|
|
2023
Q3 | $3.26K | Sell |
32
-269
| -89% | -$27.3K | ﹤0.01% | 754 |
|
|
2023
Q2 | $30.4K | Buy |
301
+163
| +118% | +$16.3K | ﹤0.01% | 432 |
|
|
2023
Q1 | $12.7K | Sell |
138
-13
| -9% | -$1.14K | ﹤0.01% | 582 |
|
|
2022
Q4 | $13.7K | Sell |
151
-22
| -13% | -$1.85K | ﹤0.01% | 546 |
|
|
2022
Q3 | $13K | Buy |
173
+120
| +226% | +$9.95K | ﹤0.01% | 530 |
|
|
2022
Q2 | $4K | Hold |
53
| – | – | ﹤0.01% | 736 |
|
|
2022
Q1 | $5K | Hold |
53
| – | – | ﹤0.01% | 774 |
|
|
2021
Q4 | $5K | Hold |
53
| – | – | ﹤0.01% | 744 |
|
|
2021
Q3 | $4K | Sell |
53
-76
| -59% | -$6.84K | ﹤0.01% | 742 |
|
|
2021
Q2 | $11K | Buy |
129
+53
| +70% | +$4.72K | ﹤0.01% | 732 |
|
|
2021
Q1 | $6K | Buy |
+76
| New | +$6.82K | ﹤0.01% | 714 |
|
|
2020
Q3 | – | Sell |
-72
| Closed | -$6K | – | 531 |
|
|
2020
Q2 | $6K | Sell |
72
-143
| -67% | -$12.3K | ﹤0.01% | 550 |
|
|
2020
Q1 | $18K | Sell |
215
-60
| -22% | -$5.35K | ﹤0.01% | 403 |
|
|
2019
Q4 | $26K | Buy |
275
+203
| +282% | +$18.2K | ﹤0.01% | 414 |
|
|
2019
Q3 | $6K | Hold |
72
| – | – | ﹤0.01% | 598 |
|
|
2019
Q2 | $7K | Buy |
+72
| New | +$6.09K | ﹤0.01% | 626 |
|
|
2017
Q4 | – | Sell |
-28,606
| Closed | -$2.2M | – | 182 |
|
|
2017
Q3 | $2.2M | Buy |
28,606
+346
| +1% | +$26.1K | 0.54% | 63 |
|
|
2017
Q2 | $2.11M | Buy |
28,260
+632
| +2% | +$44.8K | 0.55% | 63 |
|
|
2017
Q1 | $1.84M | Buy |
27,628
+859
| +3% | +$57.2K | 0.5% | 67 |
|
|
2016
Q4 | $1.75M | Sell |
26,769
-244
| -0.9% | -$15.8K | 0.52% | 68 |
|
|
2016
Q3 | $1.91M | Buy |
27,013
+3,527
| +15% | +$257K | 0.6% | 59 |
|
|
2016
Q2 | $1.74M | Buy |
23,486
+1,023
| +5% | +$70.7K | 0.59% | 63 |
|
|
2016
Q1 | $1.46M | Buy |
22,463
+2,204
| +11% | +$150K | 0.51% | 68 |
|
|
2015
Q4 | $1.56M | Buy |
20,259
+302
| +2% | +$24K | 0.57% | 60 |
|
|
2015
Q3 | $1.64M | Buy |
19,957
+995
| +5% | +$88.6K | 0.66% | 55 |
|
|
2015
Q2 | $1.67M | Buy |
18,962
+807
| +4% | +$74K | 0.64% | 52 |
|
|
2015
Q1 | $1.6M | Buy |
18,155
+937
| +5% | +$83.1K | 0.62% | 55 |
|
|
2014
Q4 | $1.43M | Buy |
17,218
+13,902
| +419% | +$1.15M | 0.59% | 61 |
|
|
2014
Q3 | $280K | Buy |
3,316
+279
| +9% | +$22.6K | 0.12% | 122 |
|
|
2014
Q2 | $246K | Buy |
3,037
+112
| +4% | +$8.81K | 0.11% | 126 |
|
|
2014
Q1 | $223K | Buy |
+2,925
| New | +$213K | 0.11% | 126 |
|
Other funds holding NVS
Stonebridge Capital Advisors's NVS Position: Q4 2023 in Review
Stonebridge Capital Advisors sold out of Novartis (NVS) in Q4 2023, closing a stake of 32 shares — an estimated $3.26K sold.
Stonebridge Capital Advisors first reported a position in NVS in Q1 2014 and held it in 31 quarters. The position peaked at $2.2M in Q3 2017. 1,272 funds tracked by Wall St. Rank hold NVS as of Q4 2023.
- Stonebridge Capital Advisors reported no remaining Novartis position as of Q4 2023 after selling out during the quarter.
- Stonebridge Capital Advisors sold 32 Novartis shares in Q4 2023, an estimated $3.26K.
- Stonebridge Capital Advisors first reported a position in Novartis in Q1 2014 and held it in 31 quarters.
- Stonebridge Capital Advisors's Novartis position peaked at $2.2M in Q3 2017.
- 1,272 funds tracked by Wall St. Rank held Novartis as of Q4 2023.
Based on Stonebridge Capital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.